The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
Sponsor: Regeneron Pharmaceuticals
This PHASE4 trial investigates Atopic Dermatitis and Atopic Dermatitis Eczema and is currently completed. Regeneron Pharmaceuticals leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE4
-
Feb 2023 — Feb 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Nov 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE4
▶ Show 7 earlier versions
-
Apr 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Apr 2022 [monthly]
Recruiting PHASE4
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Jul 2020 — Dec 2020 [monthly]
Recruiting PHASE4
-
Mar 2019 — Jul 2020 [monthly]
Recruiting PHASE4
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .